CPX-351 (Vyxeos) is a liposomal formulation of cytarabine and daunorubicin with potential antitumor activity. CPX-351 delivers these two compounds to leukemia cells in a synergistic 5:1 ratio, with higher delivery rates than in normal bone marrow cells. CPX-351 is indicated for the treatment of acute myeloid leukemia.
Molekulargewicht:
770.74
Reinheit:
98.95%
CAS Nummer:
[1256639-86-7]
Formel:
C36H42N4O15
Target-Kategorie:
Others
T31088
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten